Markets:

Overview

News

Currencies

International

Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

60 Biggest Movers From Yesterday ↗

December 07, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

FDA Raises Concerns On Reata's Kidney Disease Drug Data; Shares Plunge ↗

December 06, 2021

Reata Pharmaceuticals Inc (NASDAQ: RETA) shares are trading lower during the market trading session after the FDA released briefing documents ahead of the Advisory...

Via Benzinga

Reata Pharma Stock Dives 40% As FDA Reviewers Waffle On Kidney Disease Drug ↗

December 06, 2021

FDA experts are set to debate the drug's merits and risks on Wednesday.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 06, 2021

Gainers Adicet Bio (NASDAQ:ACET) shares i...

Via Benzinga

36 Stocks Moving In Monday's Mid-Day Session ↗

December 06, 2021

Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to acquire Del Taco Restaurants for $12.51 per share...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings ↗

December 06, 2021

Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also rose, gaining 0.59% to 4,565.21. The U.S. has...

Via Benzinga

Topics Stocks

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗

November 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...

Via Benzinga

Reata Pharmaceuticals, inc (RETA) Q3 2021 Earnings Call Transcript ↗

November 08, 2021

RETA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Reata Pharmaceuticals's Return On Capital Employed Overview ↗

November 08, 2021

According to Benzinga Pro data, during Q3, Reata Pharmaceuticals (NASDAQ:RETA) posted sales of $7.39 million. Earnings were up 3.38%, but Reata Pharmaceuticals still reported an...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Reata Pharmaceuticals: Q3 Earnings Insights ↗

November 08, 2021

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

A Preview Of Reata Pharmaceuticals's Earnings ↗

November 05, 2021

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs ↗

October 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...

Via Benzinga

Reata Pharmaceuticals's Return on Invested Capital Overview ↗

September 17, 2021

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last...

Via Benzinga

Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats ↗

August 10, 2021

The FDA pours cold water on the company's better-than-expected quarter.

Via The Motley Fool

Topics Earnings

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

Reata's Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application ↗

August 10, 2021

Reata Pharmaceuticals Inc (NASDAQ: RETA) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

28 Stocks Moving in Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...

Via Benzinga

Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

RETA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

8 Stocks Moving In Monday's After-Hours Session ↗

August 09, 2021

Gainers Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share....

Via Benzinga

Reata Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2021

Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32%...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today